v3.25.4
Revenue - Disaggregation of Revenue by Product (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Disaggregation of Revenue [Line Items]      
Revenue $ 65,179 $ 45,043 $ 34,124
U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 43,481 30,375 21,791
Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 21,698 14,668 12,333
Cardiometabolic Health | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 33,864 21,850 14,781
Cardiometabolic Health | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 14,357 7,671 4,887
Mounjaro | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 13,651 8,950 4,834
Mounjaro | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 9,315 2,590 329
Zepbound | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 13,484 4,926 176
Zepbound | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 58 0 0
Trulicity | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 2,914 3,694 5,433
Trulicity | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 1,362 1,560 1,699
Jardiance      
Disaggregation of Revenue [Line Items]      
Revenue 3,432 3,341 2,745
Jardiance | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 1,582 1,598 1,600
Jardiance | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 1,849 1,743 1,144
Other cardiometabolic health | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 2,233 2,682 2,738
Other cardiometabolic health | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 1,773 1,778 1,715
Oncology | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 5,352 5,036 3,797
Oncology | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 4,024 3,717 2,861
Verzenio | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 3,464 3,421 2,509
Verzenio | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 2,259 1,886 1,354
Other oncology | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 1,888 1,615 1,288
Other oncology | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 1,765 1,831 1,507
Immunology | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 2,964 2,458 2,058
Immunology | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 2,283 1,935 1,740
Taltz | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 2,333 2,152 1,832
Taltz | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 1,230 1,108 928
Other immunology | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 631 306 226
Other immunology | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 1,053 827 812
Neuroscience | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 997 780 696
Neuroscience | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 394 694 2,183
Other | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 304 251 459
Other | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue $ 639 $ 652 $ 663